Diagnosis and Risk Factors for Invasive Mold Infections

Well-being, Health and Biomedical Discovery

Deadlines

Academic Unit: Inquire with unit

Memorial Deadline: Monday 16th, September 2024

External Deadline: Sunday 22nd, September 2024


Description

Pfizer Global Medical Grants & Partnerships (GMGP) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfzer’s GMGP competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

Date RFP Issued: August 8, 2024

Geographic Scope: Global, excluding the United States

Clinical Area: Invasive Fungal Infections

Link to full RFP: Diagnosis and Risk Factors for Invasive Mold Infections

Application Due Date: September 22, 2024

Specific Area of Interest: Potential applicants are encouraged to address the educational needs of healthcare professionals relating to early diagnosis of invasive mold and yeast infections to improve the management of patients with IFI. This can include:

  • – Needs assessment to better understand, assess and identify knowledge gaps and opportunities for action in diagnosis and testing including understanding of risk factors.
  • – Educational tools/resources to reduce information barriers and knowledge acquisition.
    – Educational programs to improve knowledge comprehension and ensure equitable access and improved patient outcomes.
  • Refer to complete details in the full RFP document. If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Talita Honorato-Rzeszewicz (Talita.Honorato-Rzeszewicz@pfizer.com).

Funding Sources

Pfizer Inc



This opportunity was posted by: RGCS

Last modified: August 12, 2024